Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
36
MDCX Quote, Financials, Valuation and Earnings
Last price:
$2.05
Seasonality move
:
-37.34%
Day range:
$1.96 - $2.20
52-week range:
$1.68 - $8.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
14.53x
Volume:
441.3K
Avg. volume:
320.4K
1-year change:
-31.77%
Market cap:
$44.9M
Revenue:
--
EPS (TTM):
-$2.11
Analysts' Opinion
-
Consensus RatingMedicus Pharma Ltd. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $22.03, Medicus Pharma Ltd. has an estimated upside of 980.03% from its current price of $2.04.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $20.00 representing 100% downside risk from its current price of $2.04.
Fair Value
-
According to the consensus of 2 analysts, Medicus Pharma Ltd. has 980.03% upside to fair value with a price target of $22.03 per share.
MDCX vs. S&P 500
-
Over the past 5 trading days, Medicus Pharma Ltd. has overperformed the S&P 500 by 3.34% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Medicus Pharma Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Medicus Pharma Ltd. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Medicus Pharma Ltd. reported revenues of --.
Earnings Growth
-
Medicus Pharma Ltd. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Medicus Pharma Ltd. reported earnings per share of -$1.12.
Enterprise value:
43.4M
EV / Invested capital:
6.95x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-2.23x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-379.25%
Net Income Margin (TTM):
--
Return On Equity:
-1316.36%
Return On Invested Capital:
-610.17%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$1.1M | -$9.4M | -$19.6M | -$2.3M | -$6.7M | |
| EBITDA | -$3.3M | -$9.4M | -- | -$2.3M | -$6.7M | |
| Diluted EPS | -$0.57 | -$1.21 | -$2.11 | -$0.24 | -$1.12 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $5.1M | $5.4M | $9.8M | |
| Total Assets | -- | -- | $5.1M | $5.7M | $10M | |
| Current Liabilities | -- | -- | $1.6M | $2M | $10.7M | |
| Total Liabilities | -- | -- | $1.6M | $2.2M | $10.8M | |
| Total Equity | -- | -- | $3.5M | $3.5M | -$804.9K | |
| Total Debt | -- | -- | -- | $349K | $265.7K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.1M | -$10.4M | -$16.7M | -$3.1M | -$6.8M | |
| Cash From Investing | -- | -- | -$4.7M | -- | -$4.7M | |
| Cash From Financing | -- | $10.6M | $24.2M | $47.6K | $10.5M | |
| Free Cash Flow | -$1.1M | -$10.4M | -$19.4M | -$3.1M | -$6.8M | |
MDCX
Sector
Market Cap
$44.9M
$28.5M
Price % of 52-Week High
22.82%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-46.83%
-1.33%
1-Year Price Total Return
-31.77%
-20.32%
Beta (5-Year)
--
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.99
200-day SMA
Sell
Level
$3.03
Bollinger Bands (100)
Sell
Level
2.03 - 2.61
Chaikin Money Flow
Sell
Level
-14.9M
20-day SMA
Sell
Level
$2.11
Relative Strength Index (RSI14)
Sell
Level
46.87
ADX Line
Buy
Level
11.55
Williams %R
Neutral
Level
-42.5197
50-day SMA
Sell
Level
$2.29
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-4.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.1891)
Sell
CA Score
(Annual)
Level (-13.5457)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (16.5579)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops a product, SkinJectTM, with an indication for basal cell carcinoma. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.
Stock Forecast FAQ
In the current month, MDCX has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MDCX average analyst price target in the past 3 months is $22.03.
-
Where Will Medicus Pharma Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Medicus Pharma Ltd. share price will rise to $22.03 per share over the next 12 months.
-
What Do Analysts Say About Medicus Pharma Ltd.?
Analysts are divided on their view about Medicus Pharma Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Medicus Pharma Ltd. is a Sell and believe this share price will drop from its current level to $20.00.
-
What Is Medicus Pharma Ltd.'s Price Target?
The price target for Medicus Pharma Ltd. over the next 1-year time period is forecast to be $22.03 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MDCX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Medicus Pharma Ltd. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of MDCX?
You can purchase shares of Medicus Pharma Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Medicus Pharma Ltd. shares.
-
What Is The Medicus Pharma Ltd. Share Price Today?
Medicus Pharma Ltd. was last trading at $2.05 per share. This represents the most recent stock quote for Medicus Pharma Ltd.. Yesterday, Medicus Pharma Ltd. closed at $2.04 per share.
-
How To Buy Medicus Pharma Ltd. Stock Online?
In order to purchase Medicus Pharma Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get MDCX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
MDCX
Sector
P/E ratio
--
23.75x
PEG ratio
-0.01x
-0.01x
P/B ratio
14.53x
1.83x
Price / LTM sales
--
1.60x
Growth Metrics
MDCX
Sector
Revenue growth
--
4.85%
Earnings growth
-369.19%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.38
-$0.20
Profitability
MDCX
Sector
Profitability FY 2024
--
$3.6M
Return on invested capital
-610.17%
-30.98%
Return on assets
-379.25%
-27.62%
Return on equity
-1316.36%
-36.69%
Earnings Date
Last Earnings Date
Feb
24
Next Earnings Date
Mar
26
Estimated Next Earnings Date
May
26
Balance Sheet
MDCX
Sector
Total cash
$8.7M
$27.2M
Short term investments
--
$25.7M
Total assets
$3.9M
$79.7M
Long term debt
$265.7K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is up 102.52% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
